Felix Seyfried

Dr. Felix Seyfried

Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University Hospital Regensburg, Regensburg, Bavaria, Germany
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
SEStefanie Enzenmüller
Stefanie Enzenmüller
ANAlexandra Niedermayer
Alexandra Niedermayer
FSFelix Seyfried
Felix Seyfried
VMVera Muench
Vera Muench
DTDaniel Tews
Daniel Tews
LMLueder H. Meyer
Lueder H. Meyer
Deregulated apoptosis signaling is characteristic for many cancers and contributes to leukemogenesis and treatment failure in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Apoptosis is controlled by different pro- and anti-apoptotic molecules. Inhibition of anti-apoptotic molecules like B-cell lymphoma 2 (BCL-2) has been developed as therapeutic strategy. Venetoclax (VEN), a selective BCL-2 inhibitor has shown clinical activity in different lymphoid malignancies and is currently evaluated in first clinical trials in BCP-ALL. However, insensitivity to VEN has been described constituting a major clinical concern. Here, we addressed and modeled VEN-resistance in BCP-ALL, investigated the underlying mechanisms in cell lines and patient-derived xenograft (PDX) samples and identified potential strategies to overcome VEN-insensitivity. Leukemia lines with VEN-specific resistance were generated in vitro and further characterized using RNA-seq analysis. Interestingly, gene sets annotated to the citric/tricarboxylic acid cycle and the respiratory electron transport chain were significantly enriched and upregulated, indicating increased mitochondrial metabolism in VEN-resistant ALL. Metabolic profiling showed sustained high mitochondrial metabolism in VEN-resistant lines as compared to control lines. Accordingly, primary PDX-ALL samples with intrinsic VEN-insensitivity showed higher oxygen consumption and ATP production rates, further highlighting that increased mitochondrial activity is a characteristic feature of VEN-resistant ALL. VEN-resistant PDX-ALL showed significant higher mitochondrial DNA content and differed in mitochondria morphology with significantly larger and elongated structures, further corroborating our finding of augmented mitochondrial metabolism upon VEN-resistance. Using Oligomycin, an inhibitor of the complex V/ATPase subunit, we found synergistic activity and apoptosis induction in VEN-resistant BCP-ALL cell lines and PDX samples, demonstrating that acquired and intrinsic VEN-insensitivity can be overcome by co-targeting BCL-2 and the OxPhos pathway. These findings of reprogrammed, high mitochondrial metabolism in VEN-resistance and synergistic activity upon co-targeting BCL-2 and oxidative phosphorylation strongly suggest further preclinical and potential clinical evaluation in VEN-resistant BCP-ALL.

15 April 2025 in Leukemia
Verified
Journal Article
Open access
PDF file
ANAlexandra Niedermayer
Alexandra Niedermayer
JSJana Stursberg
Jana Stursberg
ABAnke Katharina Bergmann
Anke Katharina Bergmann
MZMartin Zimmermann
Martin Zimmermann
GCGunnar Cario
Gunnar Cario
KDKlaus-Michael Debatin
Klaus-Michael Debatin

27 November 2024 in Blood Advances
Verified
Journal Article
Open access
MWMaren Christiane Wichert
Maren Christiane Wichert
CFColin Fortner
Colin Fortner
ANAlexandra Niedermayer
Alexandra Niedermayer
JBJohanna Bender
Johanna Bender
SEStefanie Enzenmüller
Stefanie Enzenmüller
FSFelix Seyfried
Felix Seyfried

2 May 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
BJBilly Michael Chelliah Jebaraj
Billy Michael Chelliah Jebaraj
MLMichael Liew
Michael Liew
FSFelix Seyfried
Felix Seyfried

4 April 2026 in Cell Death & Disease
Verified
Journal Article
Open access
CFColin Fortner
Colin Fortner
ANAlexandra Niedermayer
Alexandra Niedermayer
MBMelina Maria Bäuerle
Melina Maria Bäuerle
MWMaren Christiane Wichert
Maren Christiane Wichert
CBChristian Jörg Braun
Christian Jörg Braun
FSFelix Seyfried
Felix Seyfried
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of T-cell precursors. Although the survival rates have improved with the use of intensive chemotherapy, the emergence of relapse as well as treatment-related morbidity and mortality remain major challenges. Novel treatment approaches include the inhibition of anti-apoptotic regulators or cellular immunotherapies. Here, we analyzed the sensitivity of T-ALL to inhibitors of BCL-2 (venetoclax), BCL-XL (A1331852), MCL-1 (AZD5991) and dual inhibition of BCL-2/BCL-XL (AZD4320) and evaluated their combination effects with natural killer (NK) cells. While only early T-cell precursor (ETP) ALL was sensitive to BCL-2 inhibition, MCL-1 inhibition alone was not effective in most cell lines and patient-derived xenograft (PDX) samples. For BCL-XL and dual BCL-2/BCL-XL inhibition, we observed heterogeneous sensitivities, which were associated with anti-apoptotic dependencies on the respective BCL-2 family members as assessed by BH3-profiling. Moreover, we identified functional shifts in anti-apoptotic dependencies upon exposure to AZD4320 or AZD5991 alone and synergistic effects when both inhibitors were combined with each other, allowing cell death induction in resistant samples. We then explored the potential use of apoptosis-inducing drugs as sensitizers for immunotherapy. Therefore, we investigated the potential of NK cell-mediated killing in T-ALL and found heterogeneous sensitivity, with some cell lines showing responses even at low effector-to-target (E:T) ratios. Importantly, NK cell-mediated killing could be further enhanced by combining NK cells with AZD4320, proposing this combination as a potential effective treatment. Taken together, we demonstrated promising potential of BH3-mimetics and NK cells for the treatment of T-ALL alone and in combination, warranting further preclinical and potential clinical evaluation.

27 April 2012 in Klinische Padiatrie
Verified
Journal Article
Closed access
FSFelix Seyfried
Felix Seyfried
BABenedetta Accordi
Benedetta Accordi
MQManon Queudeville
Manon Queudeville
SESm Eckhoff
Sm Eckhoff
GMG Milani
G Milani
LMLh Meyer
Lh Meyer
In a NOD/SCID/huALL model we have recently shown that short time to leukemia (TTLshort) of xenografted patient samples determines poor patient outcome. In this study we analyzed 16 xenografted BCP-ALL samples using RPPA and validated the findings by Western Blot. Comparison of the protein expression data in short vs. long TTL subgroups (shrinkage t-test, P<0.05, fold change ≥1.5) revealed up-regulation of CYCLIN B, ß-CATENIN and ANNEXIN I and down-regulated PKCd in TTLshort ALL. Consistently, CYCLIN B is a positive regulator of the cell cycle suggesting an association of cell cycle progression and NOD/SCID engraftment. ß-CATENIN is involved in WNT-signaling and associated with apoptosis inhibition and cell growth. ANNEXIN I is a regulator of inflammation and reported to be over-expressed in hairy cell leukemia. In contrast, down-regulated PKCd has also been reported in poor prognostic T-ALL patients. Taken together, this study identified differenzially expressed proteins in prognostic subgroups of BCP-ALL patients with distinct clinical outcomes, which can be further evaluated as new prognostic markers and therapeutic targets.